Neoadjuvant therapy 1

Phase 2Small molecule

TTang-Du Hospital

Neoadjuvant therapy 1 is one of 62 small molecule programs targeting Pleural Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural MesotheliomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pleural MesotheliomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Neoadjuvant therapy 1

TTang-Du Hospital

Phase 2

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

PD-1 Inhibitor

NCT05400070

Q4 2027

N/ANot yet recruiting

Gastroesophageal Junction Carcinoma

NCT07092449

Q3 2029

Phase 1/2Recruiting

Pleural Mesothelioma

NCT07121374

Clinical

Trials by Indication[1]

Gastroesophageal Junction Carcinoma1 trial

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

Not yet recruiting·TTang-Du Hospital·N/A·NCT07092449·30 enrolled

Pleural Mesothelioma1 trial

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT07121374·37 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Recruiting·SSun Yat-sen University·Phase 2·NCT05468242·116 enrolled

PD-1 Inhibitor1 trial

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Active, not recruiting·TTang-Du Hospital·Phase 2·NCT05400070·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Neoadjuvant therapy 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant therapy 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant therapy 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Neoadjuvant therapy 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2029

Trials by Indication[1]

Gastroesophageal Junction Carcinoma1 trial

Pleural Mesothelioma1 trial

Non-Small Cell Lung Cancer1 trial

PD-1 Inhibitor1 trial

References

Drug Info

Quick Facts

Related News